Amplia Therapeutics Ltd (ATX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Amplia Therapeutics Ltd (ATX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7969
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Amplia Therapeutics Ltd (Amplia Therapeutics), formerly Innate Therapeutics Ltd, is a pharmaceutical company with focus on the development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. Its lead drug candidate, AMP945, is a small molecule targeting focal adhesion kinase (FAK) in fibrotic tumors such as pancreatic and ovarian cancer; and the other drug candidate AMP886 is a multi-action molecule targeting VEGFR3 and FLT3 cancer pathways in solid and hematological cancers. As FAK is a significant target in cancer immunology, the company has focus on FAK inhibitors for treating cancers and chronic diseases such as idiopathic pulmonary fibrosis. Amplia Therapeutics is headquartered in Melbourne, Victoria, Australia.

Amplia Therapeutics Ltd (ATX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD0.2 Million in Private Placement of Shares 12
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 13
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 15
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 17
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 18
Innate Immunotherapeutics Completes IPO For US$9 Million 19
Acquisition 21
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 21
Amplia Therapeutics Ltd – Key Competitors 22
Amplia Therapeutics Ltd – Key Employees 23
Amplia Therapeutics Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Jul 30, 2018: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report of the year 2018 25
Corporate Communications 26
May 28, 2018: Innate Immunotherapeutics Names Dr. Warwick Tong As Chairman 26
Legal and Regulatory 27
Aug 08, 2018: Congressman Christopher Collins And Others Charged In Manhattan Federal Court With Insider Trading And Lying To Federal Law Enforcement Agents 27
Product News 30
06/21/2017: Innate Immunotherapeutics receives FDA clearance for MIS416 Investigational New Drug application 30
03/07/2017: Multiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists Meeting 31
Clinical Trials 32
Oct 20, 2017: Innate Immunotherapeutics Provides Corporate Update 32
Jul 21, 2017: No change to outcome of MIS416 trial in patients with SPMS following additional data analysis 33
Jun 27, 2017: Innate Immunotherapeutics announces top-line results for trial of MIS416 in patients with secondary progressive multiple sclerosis 34
Apr 20, 2017: Completion of Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis 36
Feb 28, 2017: Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis on schedule to complete by end of April 2017 37
Other Significant Developments 38
Sep 05, 2018: Innate Immunotherapeutics changes name to Amplia Therapeutics and ASX stock code to ATX 38
Oct 30, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 39
Jul 28, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD0.2 Million in Private Placement of Shares 12
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 13
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 15
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 17
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 18
Innate Immunotherapeutics Completes IPO For US$9 Million 19
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 21
Amplia Therapeutics Ltd, Key Competitors 22
Amplia Therapeutics Ltd, Key Employees 23
Amplia Therapeutics Ltd, Subsidiaries 24

List of Figures
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Amplia Therapeutics Ltd (ATX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Assertio Therapeutics Inc (DEPO):製薬・医療:M&Aディール及び事業提携情報
    Summary Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of the central nervous system. Its product portfolio comprises drugs for the treatment of postherpetic neuralg …
  • DiaCarta Inc:企業の製品パイプライン分析2018
    Summary DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection ki …
  • Planung Transport Verkehr AG:企業の戦略的SWOT分析
    Planung Transport Verkehr AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Sarawak Energy Bhd:企業の戦略的SWOT分析
    Sarawak Energy Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Calumet Specialty Products Partners LP (CLMT):企業の財務・戦略的SWOT分析
    Calumet Specialty Products Partners LP (CLMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Danieli & C. Officine Meccaniche SpA:企業の戦略・SWOT・財務情報
    Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report Summary Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Meritage Homes Corporation:企業の戦略・SWOT・財務情報
    Meritage Homes Corporation - Strategy, SWOT and Corporate Finance Report Summary Meritage Homes Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Fiesta Mart, Inc.:企業の戦略的SWOT分析
    Fiesta Mart, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • EVN AG:企業の発電所・SWOT分析2018
    EVN AG - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • TG Therapeutics Inc (TGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the tr …
  • FANUC CORPORATION:企業の戦略・SWOT・財務分析
    FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report Summary FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Protege Energy III LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Protege Energy III LLC (Protege Energy) is an oil and gas exploration and production company. The company offers acquisition and development of oil and gas reserves including exploration, development, operations, horizontal drilling, reservoir stimulations, recompletions, artificial lift and …
  • Sorrento Therapeutics Inc (SRNE):企業の財務・戦略的SWOT分析
    Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Stada Arzneimittel AG (SAZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of product …
  • Korea National Oil Corporation-石油・ガス分野:企業M&A・提携分析
    Summary Korea National Oil Corporation (KNOC) is a state-owned integrated energy company that carries out the exploration, development and production of oil and gas, and stockpiling of petroleum resources. The company purchases and sells crude oil, distribute gasoline and gasoline oil and sells refi …
  • Pan American Silver Corp:企業の戦略・SWOT・財務情報
    Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report Summary Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Spectra Energy Partners, LP (SEP)-石油・ガス分野:企業M&A・提携分析
    Summary Spectra Energy Partners, LP (Spectra Energy), a subsidiary of Enbridge Inc., is master limited partnership operating in mid-stream energy. The company conducts transmission, storage and gathering of natural gas. It also carries out the transportation and storage of crude oil, and the transpo …
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. Its pipeline products include Leronlimab (PRO 140), a ful …
  • Peyto Exploration & Development Corp (PEY):企業の財務・戦略的SWOT分析
    Summary Peyto Exploration & Development Corp (Peyto Exploration & Development) is an oil and gas exploration and development company that acquires, explores, develops and produces crude oil and unconventional natural gas reserves. The company operates the Alberta Deep Basin, a geologic setting locat …
  • Subsea 7 SA (SUBC):石油・ガス:M&Aディール及び事業提携情報
    Summary Subsea 7 SA (Subsea 7) is a contractor in seabed-to-surface engineering, construction and services. The company provides engineering, project management, supply chain, and vessel management services. It connects seabed wellhead structures to surface facilities, such as platforms and floating …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆